Addex spin-out Neurosterix raises $105 million in Series B round
Addex's stake in Neurosterix now stands at 8.5%, with the new funds aimed mainly at advancing NTX-253 into Phase 2 testing for schizophrenia.
SEC filing
2 stories
Addex's stake in Neurosterix now stands at 8.5%, with the new funds aimed mainly at advancing NTX-253 into Phase 2 testing for schizophrenia.
SEC filing
Rocher returns from Neurosterix retirement while Mikhail Kalinichev steps down to focus full time on his Neurosterix role.
SEC filing